ES2912284T3 - Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa - Google Patents

Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa Download PDF

Info

Publication number
ES2912284T3
ES2912284T3 ES18165005T ES18165005T ES2912284T3 ES 2912284 T3 ES2912284 T3 ES 2912284T3 ES 18165005 T ES18165005 T ES 18165005T ES 18165005 T ES18165005 T ES 18165005T ES 2912284 T3 ES2912284 T3 ES 2912284T3
Authority
ES
Spain
Prior art keywords
alkyl
methyl
phenyl
substituted
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18165005T
Other languages
English (en)
Spanish (es)
Inventor
Juan Jose Marugan
Noel Southall
M Ehud Goldin
Samarjit Patnaik
Ellen Sidransky
Omid Motabar
Wendy Westbrook
Wei Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Application granted granted Critical
Publication of ES2912284T3 publication Critical patent/ES2912284T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES18165005T 2010-12-08 2011-12-08 Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa Active ES2912284T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42094610P 2010-12-08 2010-12-08

Publications (1)

Publication Number Publication Date
ES2912284T3 true ES2912284T3 (es) 2022-05-25

Family

ID=45498099

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18165005T Active ES2912284T3 (es) 2010-12-08 2011-12-08 Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa
ES11810714.3T Active ES2681218T3 (es) 2010-12-08 2011-12-08 Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11810714.3T Active ES2681218T3 (es) 2010-12-08 2011-12-08 Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa

Country Status (24)

Country Link
US (3) US9353117B2 (enExample)
EP (2) EP3366688B1 (enExample)
JP (1) JP6154746B2 (enExample)
KR (1) KR101931224B1 (enExample)
CN (1) CN103534255B (enExample)
AU (1) AU2011338377B2 (enExample)
BR (1) BR112013014242B1 (enExample)
CA (1) CA2820362C (enExample)
CY (1) CY1125186T1 (enExample)
DK (2) DK2649075T3 (enExample)
ES (2) ES2912284T3 (enExample)
HR (1) HRP20220512T1 (enExample)
HU (1) HUE038635T2 (enExample)
IL (2) IL226767B (enExample)
LT (1) LT3366688T (enExample)
MX (2) MX385600B (enExample)
PL (2) PL3366688T3 (enExample)
PT (2) PT3366688T (enExample)
RS (1) RS63320B1 (enExample)
RU (1) RU2603637C2 (enExample)
SI (2) SI2649075T1 (enExample)
TR (1) TR201810523T4 (enExample)
WO (1) WO2012078855A1 (enExample)
ZA (1) ZA201304215B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3366688T3 (pl) 2010-12-08 2022-05-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
AP2013007331A0 (en) 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
KR20140077963A (ko) * 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3215505B1 (en) 2014-11-03 2019-07-24 Bayer Pharma Aktiengesellschaft Piperidinylpyrazolopyrimidinones and their use
EP3215511B1 (en) * 2014-11-06 2024-04-17 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2017004408A1 (en) 2015-07-01 2017-01-05 Northwestern University Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
US20190092789A1 (en) * 2015-09-04 2019-03-28 Lysosomal Therapeutics Inc. Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
WO2017040879A1 (en) * 2015-09-04 2017-03-09 Lysosomal Therapeutics Inc. Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017161137A1 (en) * 2016-03-16 2017-09-21 Lysosomal Therapeutics Inc. Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
MX388912B (es) * 2016-04-06 2025-03-20 Lysosomal Therapeutics Inc Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
KR20180133461A (ko) * 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192929A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018083085A1 (en) * 2016-11-02 2018-05-11 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
EP3661919A4 (en) 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
EP3747885A4 (en) 2018-01-31 2021-11-03 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
US10882865B2 (en) 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
EP3849981B1 (en) 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
CA3151850A1 (en) * 2019-08-21 2021-02-25 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes (sting)
CA3150700A1 (en) 2019-09-17 2021-03-25 Renato T. Skerlj IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CN114901652A (zh) 2019-09-17 2022-08-12 比亚尔R&D投资股份公司 用于治疗医学病症的经取代的饱和和不饱和n-杂环甲酰胺及相关化合物
CA3151022A1 (en) 2019-09-17 2021-03-25 Bial - R&D Investments, S.A. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
JP7890737B2 (ja) * 2019-11-25 2026-07-15 ジーティー ゲイン セラピューティクス エスアー ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用
TWI810520B (zh) 2020-02-12 2023-08-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
CA3167313A1 (en) 2020-02-12 2021-08-19 Thomas John Bleisch Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
US20250230172A1 (en) * 2021-10-13 2025-07-17 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
CA3235270A1 (en) * 2021-10-13 2023-04-20 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037373A2 (en) 2002-10-21 2004-05-06 The Scripps Research Institute CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE
JP2004277337A (ja) * 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
EP1615697A2 (en) * 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
US20050137223A1 (en) 2003-11-12 2005-06-23 Amicus Therapeutics, Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
CA2507348C (en) * 2004-05-13 2013-07-16 The Hospital For Sick Children Real time methylumbelliferone-based assay
EP1753422B1 (en) 2004-05-14 2008-05-28 The Cleveland Clinic Foundation Small molecule inhibitors for mrp1 and other multidrug transporters
ATE383361T1 (de) * 2004-06-21 2008-01-15 Hoffmann La Roche Pyrrazolopyrimidinderivate
DE102005007534A1 (de) * 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP5463034B2 (ja) 2005-05-20 2014-04-09 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
MX2008002014A (es) * 2005-08-15 2008-03-27 Hoffmann La Roche Derivados de piperidina y piperazina como antagonistas de p2x3.
CA2626789A1 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
US8188097B2 (en) * 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
WO2008054947A2 (en) 2006-10-02 2008-05-08 The Brigham And Women's Hospital, Inc. Structure of acid beta-glucosidase and methods for identifying therapeutic agents
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
US20080176870A1 (en) 2006-11-20 2008-07-24 Bert Nolte Heterobicyclic metalloprotease inhibitors
MX2009011055A (es) 2007-04-13 2010-01-13 Amicus Therapeutics Inc Tratamiento de la enfermedad de gaucher con chaperonas farmacologicas especificas y supervision del tratamiento utilizando marcadores sustitutos.
WO2008134035A1 (en) 2007-04-27 2008-11-06 Panacos Pharmaceuticals, Inc. Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives
CN104383556B (zh) 2007-05-16 2018-06-05 布里格姆妇女医院 突触核蛋白病的治疗
US20090118135A1 (en) 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
WO2009049422A1 (en) 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN104530052A (zh) * 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
EP2307440A4 (en) 2008-07-01 2012-12-19 Zacharon Pharmaceuticals Inc HEPARAN SULFATE INHIBITORS
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
PL3366688T3 (pl) * 2010-12-08 2022-05-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
EP3215511B1 (en) * 2014-11-06 2024-04-17 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders

Also Published As

Publication number Publication date
SI3366688T1 (sl) 2022-07-29
US9353117B2 (en) 2016-05-31
IL226767B (en) 2018-06-28
PT3366688T (pt) 2022-05-11
ZA201304215B (en) 2014-03-26
PL3366688T3 (pl) 2022-05-23
CN103534255B (zh) 2016-12-21
KR101931224B1 (ko) 2018-12-20
TR201810523T4 (tr) 2018-08-27
CY1125186T1 (el) 2024-12-13
BR112013014242A2 (pt) 2018-06-26
EP3366688B1 (en) 2022-02-09
PT2649075T (pt) 2018-07-30
AU2011338377B2 (en) 2016-08-04
EP2649075A1 (en) 2013-10-16
CN103534255A (zh) 2014-01-22
US20140249145A1 (en) 2014-09-04
KR20140010012A (ko) 2014-01-23
US20160346284A1 (en) 2016-12-01
US9974789B2 (en) 2018-05-22
ES2681218T3 (es) 2018-09-12
JP2013544893A (ja) 2013-12-19
MX2013006462A (es) 2013-10-01
MX385600B (es) 2025-03-18
IL259648A (en) 2018-07-31
WO2012078855A1 (en) 2012-06-14
HUE038635T2 (hu) 2018-11-28
AU2011338377A8 (en) 2015-10-29
LT3366688T (lt) 2022-05-25
RU2603637C2 (ru) 2016-11-27
AU2011338377A1 (en) 2013-07-04
HRP20220512T1 (hr) 2022-05-27
RS63320B1 (sr) 2022-07-29
JP6154746B2 (ja) 2017-06-28
DK3366688T3 (da) 2022-05-02
US10925874B2 (en) 2021-02-23
RU2013126094A (ru) 2015-01-20
PL2649075T3 (pl) 2018-09-28
IL259648B (en) 2021-03-25
DK2649075T3 (en) 2018-07-30
EP3366688A1 (en) 2018-08-29
CA2820362A1 (en) 2012-06-14
MX354506B (es) 2018-01-16
SI2649075T1 (sl) 2018-10-30
BR112013014242B1 (pt) 2022-02-22
CA2820362C (en) 2020-03-24
US20180263988A1 (en) 2018-09-20
EP2649075B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
ES2681218T3 (es) Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa
CA3129019A1 (en) Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor
CN106488918B (zh) 三唑并嘧啶酮或三唑并吡啶酮衍生物及其用途
US20190161476A1 (en) Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine
ES2644082T3 (es) 2-alquil-1-oxo-n-fenil-3-heteroaril-1,2,3,4-tetrahidroisoquinolina-4-carboxamidas sustituidas para tratamientos antipalúdicos
ES2893001T3 (es) Nuevos derivados de dihidropiranopirimidinona y su uso
US11440898B2 (en) Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
KR20260025059A (ko) 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물
HK40014193B (en) Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
HK40014193A (en) Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase